Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

276 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The REQUITE project: validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in cancer survivors.
West C, Azria D, Chang-Claude J, Davidson S, Lambin P, Rosenstein B, De Ruysscher D, Talbot C, Thierens H, Valdagni R, Vega A, Yuille M. West C, et al. Among authors: valdagni r. Clin Oncol (R Coll Radiol). 2014 Dec;26(12):739-42. doi: 10.1016/j.clon.2014.09.008. Epub 2014 Sep 27. Clin Oncol (R Coll Radiol). 2014. PMID: 25267305 No abstract available.
Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study.
Di Muzio NG, Fodor A, Noris Chiorda B, Broggi S, Mangili P, Valdagni R, Dell'Oca I, Pasetti M, Deantoni CL, Chiara A, Berardi G, Briganti A, Calandrino R, Cozzarini C, Fiorino C. Di Muzio NG, et al. Among authors: valdagni r. Clin Oncol (R Coll Radiol). 2016 Aug;28(8):490-500. doi: 10.1016/j.clon.2016.02.005. Epub 2016 Mar 5. Clin Oncol (R Coll Radiol). 2016. PMID: 26961088 Clinical Trial.
REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer.
Seibold P, Webb A, Aguado-Barrera ME, Azria D, Bourgier C, Brengues M, Briers E, Bultijnck R, Calvo-Crespo P, Carballo A, Choudhury A, Cicchetti A, Claßen J, Delmastro E, Dunning AM, Elliott RM, Fachal L, Farcy-Jacquet MP, Gabriele P, Garibaldi E, Gómez-Caamaño A, Gutiérrez-Enríquez S, Higginson DS, Johnson K, Lobato-Busto R, Mollà M, Müller A, Payne D, Peleteiro P, Post G, Rancati T, Rattay T, Reyes V, Rosenstein BS, De Ruysscher D, De Santis MC, Schäfer J, Schnabel T, Sperk E, Symonds RP, Stobart H, Taboada-Valladares B, Talbot CJ, Valdagni R, Vega A, Veldeman L, Ward T, Weißenberger C, West CML, Chang-Claude J; REQUITE consortium. Seibold P, et al. Among authors: valdagni r. Radiother Oncol. 2019 Sep;138:59-67. doi: 10.1016/j.radonc.2019.04.034. Epub 2019 May 27. Radiother Oncol. 2019. PMID: 31146072 Free article.
A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort.
Massi MC, Gasperoni F, Ieva F, Paganoni AM, Zunino P, Manzoni A, Franco NR, Veldeman L, Ost P, Fonteyne V, Talbot CJ, Rattay T, Webb A, Symonds PR, Johnson K, Lambrecht M, Haustermans K, De Meerleer G, de Ruysscher D, Vanneste B, Van Limbergen E, Choudhury A, Elliott RM, Sperk E, Herskind C, Veldwijk MR, Avuzzi B, Giandini T, Valdagni R, Cicchetti A, Azria D, Jacquet MF, Rosenstein BS, Stock RG, Collado K, Vega A, Aguado-Barrera ME, Calvo P, Dunning AM, Fachal L, Kerns SL, Payne D, Chang-Claude J, Seibold P, West CML, Rancati T. Massi MC, et al. Among authors: valdagni r. Front Oncol. 2020 Oct 15;10:541281. doi: 10.3389/fonc.2020.541281. eCollection 2020. Front Oncol. 2020. PMID: 33178576 Free PMC article.
External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort.
Rattay T, Seibold P, Aguado-Barrera ME, Altabas M, Azria D, Barnett GC, Bultijnck R, Chang-Claude J, Choudhury A, Coles CE, Dunning AM, Elliott RM, Farcy Jacquet MP, Gutiérrez-Enríquez S, Johnson K, Müller A, Post G, Rancati T, Reyes V, Rosenstein BS, De Ruysscher D, de Santis MC, Sperk E, Stobart H, Symonds RP, Taboada-Valladares B, Vega A, Veldeman L, Webb AJ, West CM, Valdagni R, Talbot CJ; REQUITE consortium. Rattay T, et al. Among authors: valdagni r. Front Oncol. 2020 Oct 30;10:575909. doi: 10.3389/fonc.2020.575909. eCollection 2020. Front Oncol. 2020. PMID: 33216838 Free PMC article.
Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity.
Franco NR, Massi MC, Ieva F, Manzoni A, Paganoni AM, Zunino P, Veldeman L, Ost P, Fonteyne V, Talbot CJ, Rattay T, Webb A, Johnson K, Lambrecht M, Haustermans K, De Meerleer G, de Ruysscher D, Vanneste B, Van Limbergen E, Choudhury A, Elliott RM, Sperk E, Veldwijk MR, Herskind C, Avuzzi B, Noris Chiorda B, Valdagni R, Azria D, Farcy-Jacquet MP, Brengues M, Rosenstein BS, Stock RG, Vega A, Aguado-Barrera ME, Sosa-Fajardo P, Dunning AM, Fachal L, Kerns SL, Payne D, Chang-Claude J, Seibold P, West CML, Rancati T; REQUITE Consortium Collaborators. Franco NR, et al. Among authors: valdagni r. Radiother Oncol. 2021 Jun;159:241-248. doi: 10.1016/j.radonc.2021.03.024. Epub 2021 Apr 8. Radiother Oncol. 2021. PMID: 33838170 Free PMC article.
Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer.
Kerns SL, Amidon Morlang A, Lee SM, Peterson DR, Marples B, Zhang H, Bylund K, Rosenzweig D, Hall W, De Ruyck K, Rosenstein BS, Stock RG, Gómez-Caamaño A, Vega A, Sosa-Fajardo P, Taboada-Valladares B, Aguado-Barrera ME, Parker C, Veldeman L, Fonteyne V, Bultijnck R, Talbot CJ, Symonds RP, Johnson K, Rattay T, Webb A, Lambrecht M, de Ruysscher D, Vanneste B, Choudhury A, Elliott RM, Sperk E, Herskind C, Veldwijk MR, Rancati T, Avuzzi B, Valdagni R, Azria D, Farcy Jacquet MP, Chang-Claude J, Seibold P, West C, Janelsins M, Chen Y, Messing E, Morrow G; REQUITE Consortium. Kerns SL, et al. Among authors: valdagni r. Radiother Oncol. 2022 Mar;168:75-82. doi: 10.1016/j.radonc.2022.01.014. Epub 2022 Jan 22. Radiother Oncol. 2022. PMID: 35077710 Free PMC article.
Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study).
Van der Weijst L, Aguado-Barrera ME, Azria D, Berkovic P, Boisselier P, Briers E, Bultijnck R, Calvo-Crespo P, Chang-Claude J, Choudhury A, Defraene G, Demontois S, Dunning AM, Elliott RM, Ennis D, Faivre-Finn C, Franceschini M, Gutiérrez-Enríquez S, Herskind C, Higginson DS, Kerns SL, Johnson K, Mollà M, Lambrecht M, Ramos M, Rancati T, Rimner A, Rosenstein BS, De Ruysscher D, Salem A, Sangalli C, Seibold P, Sosa-Fajardo P, Sperk E, Stobart H, Summersgill H, Surmont V, Symonds P, Taboada-Lorenzo B, Talbot CJ, Valdagni R, Vega A, Veldeman L, Veldwijk MR, Ward T, Webb A, West CML; REQUITE Consortium; Lievens Y. Van der Weijst L, et al. Among authors: valdagni r. Lung Cancer. 2022 Apr;166:228-241. doi: 10.1016/j.lungcan.2022.03.010. Epub 2022 Mar 15. Lung Cancer. 2022. PMID: 35334417 Free PMC article.
276 results